Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

Figure 3

Plasma CXCL13 at 0 and 6 months, in patients with high- and low-level CXCL13 in the treatment groups. Plasma levels of CXCL13 at 0 and 6 months in the DMARD group, the DMARD + ADA group and all patients, subdivided into `CXCL13-high' and `CXCL13-low' according to baseline level of CXCL13 ≥100 vs. <100. ***Indicates P <0.001, **: P <0.01, and ns: P >0.05. ADA: adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us